Banner
Banner
Bioscreening Company Directory

BioTek Instruments

BioTek Instruments 100 Tigan Street
05404 Winooski United States
Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Website

BioTek Instruments, Inc. is a global leader in the development, manufacture and sale of microplate instrumentation and software. The company's origins date back to 1968, when Dr. Norman Alpert, a physiologist at the University of Vermont Medical College, founded BioTek. Dedicated to providing test equipment solutions for the hospital safety and quality assurance markets, BioTek's Biomedical Division grew to become one of the largest and most successful companies in the field. Looking to expand into a growing Life Science market and capitalize on the increasing popularity of non-isotopic immunoassays, BioTek entered the microplate instrument arena, and in 1981 introduced its first microplate reader. Since then, BioTek has emerged as a global leader in microplate-based solutions that increase the productivity for customers engaged in healthcare, pharmaceutical, agricultural and research applications. With the sale of the Biomedical Division in 2002, BioTek today is completely focused on microplate instrumentation, automation and software and continues to be a privately held, family-run organization.  Briar Alpert, President & CEO, and Adam Alpert, VP of Business Development, (pictured at right) take pride in maintaining the corporate culture their father inspired and providing world-class instruments and solutions that help accelerate life science research. Click here to see a BioTek History Timeline from 1981 to present.

Get a Better Reaction

Creating the world's finest microplate instrumentation and software is only part of what makes BioTek unique. We combine an innovative development process with unwavering dedication to customer service to help eliminate roadblocks in the scientific discovery process. BioTek promises to consistently exceed your expectations and is committed to achieving excellence in every facet of our business. When you contact a member of our team, you will Get a Better Reaction.

Better Product Design

Our multi-functional Project Teams have a remarkable in-house knowledge base including expertise in molecular biology, biochemistry, mechanics, electronics, optics, micro-fluidics, software, systems, service, and manufacturing technology. Today's new product innovations are a result of our entire staff listening and reacting to the needs of our customers. We also pay careful attention to trends in evolving technology and new applications to provide a fresh perspective when designing new products and enhancements. By doing so, we consistently deliver more performance and flexibility to our customers – at a reasonable price.

Better Customer Service

Customers cite our service and support, both pre- and post-sale, to be equally as important as the quality and performance of our instrumentation. Not only do we strive for this premier level of service, but we also measure it. Each month we commission an independent organization to randomly select and query a group of customers and potential customers. These surveys measure our performance in both pre-sale and post-sale customer support. Each month, BioTek continues to meet or exceed the expectations of both groups by more than 95%!

Better Quality Control

Our employees are committed to maintaining the high quality of our products and services. Our continual improvement process includes soliciting customer input on quality and product features, and then designing, validating, manufacturing, and testing products to ensure performance and reliability as part of our ISO 9001 Quality System registration. This program guarantees independent audits of all aspects of products and services that we offer.

Product compliance to U.S. and International requirements is necessary from the design stage to final test.

  • Products are directly or indirectly measurement traceable to the U.S. National Institute of Standards and Technology (NIST) and listed with the U.S. Food and Drug Administration (FDA) when appropriate.
  • Product designs are type tested to ensure safe operation per Underwriters Laboratory (UL), Canadian Standards Association (CSA), and International Electrotechnical Commission (IEC) standards. Most bear the TUV Mark for safety based on these tests and ongoing plant surveillance.
  • New and modified designs are subject to stringent Electromagnetic Compatibility (EMC) testing to ensure products will not interfere with other equipment, and can be expected to run reliably in customers' facilities. The CE Mark on products guarantees this testing was successfully conducted.
  • Software is designed, tested, and documented in compliance with FDA and ISO guidelines.

Manufacturing uses multi-functional teams to ensure continuous and adequate support for each product type at each manufacturing phase. Innovative pull system techniques and materials management systems are utilized to reduce lead times and minimize unnecessary costs.

BioTek is ISO9001/ISO13485 Certified, an FDA Registered Medical Device Manufacturer, and has appropriate products in compliance with the EU In Vitro Diagnostic Directive (IVDD). Our quality extends to your laboratory as well. BioTek offers optional validation (IQ/OQ/PQ) and FDA 21CFR Part 11 tools to ensure regulatory compliance. Learn more about BioTek's Quality Commitment here.

Better Reach

BioTek is headquartered in Vermont, USA with global sales, service and distribution support. Our German-based subsidiary and Coordination Center, located in Bad Friedrichshall, provides marketing, service and technical support for our European distribution, along with local technical and application specialists that work in partnership with our distribution channels. BioTek has established direct offices in China, Singapore, India, France, the UK and Switzerland and continues to expand direct support in other global markets. We are continually investing to guarantee the same level of service for our instrumentation worldwide.

Our company-wide commitment to quality and value - which is backed by superior customer service, technical support centers, scientific application groups and a deeply knowledgeable sales force - means your processes will be rapid, efficient and successful. From facilitating the drug discovery process to advancing life science research and clinical diagnostics, BioTek helps you Get a Better Reaction.

Microplate Instrumentation & Software

At BioTek, we strive to be the leader in each of our product segments, and constantly perfect our technologies to reflect this position. Today's new product innovations are a result of listening and reacting to the needs of our customers and paying careful attention to trends in evolving technologies and applications. By designing new products and enhancements with this fresh perspective, we consistently deliver more performance, flexibility and value to our customers.

Detection

BioTek offers a comprehensive portfolio of innovative microplate detection instruments that lead the market in versatility, performance and value. These first-in-class products complement a broad portfolio of applications in Drug Discovery, Life Science Research and Clinical Diagnostics. Used stand-alone or seamlessly integrated into automated systems, BioTek's detection technologies ensure you will "Get a Better Reaction."

Liquid Handling

BioTek's accurate, precise and flexible suite of advanced liquid handling technologies include the market leading EL406 Microplate Washer Dispenser, reagent dispensers and automated pipetting systems. These automation friendly, multi-functional instruments increase efficiency and productivity for a wide range of applications in Drug Discovery, Life Science Research and Clinical Diagnostics.

Robotics

BioTek's BioStack series of robotic products provide speed, flexibility and unattended operation when seamlessly configured with our line of detection, liquid handling and washing products. The result is a scalable, cost-effective system that can adapt to your changing requirements.

Software

BioTek's software solutions are designed to maximize efficiency and increase the functionality of our detection and liquid handling instruments. These intuitive products are developed by programmers experienced in microplate applications.

Accessories

Search for accessories for your instrumentation or software.

 

Products

  • Gen5™ Microplate Data Analysis Software
  • Multidetection Microplate Reader
  • Liquid-Handling Control Software
  • Microplate Washer Dispenser
  • Parallelism Analysis
  • Microplate Reader
  • Magnetic Bead Washer
  • Multivolume Spectrophotometer System
  • Hybrid Microplate Reader
  • Microplate Washer
  • Alpha Microplate Reader
  • Microplate Reader
  • Microplate Dispenser
  • Vacuum Filtration Module
  • Deep Well Washer
  • Deep Well Washer

WaySearch
  
Powered by Sigsiu.NET RSS Feeds
ScienceDaily (May 16, 2012) — Microscopes provide valuable insights in the structure and dynamics of cells, in particular when the latter remain in their natural environment. However, this is very difficult especially for higher organisms. Researchers of Karlsruhe Institute of Technology (KIT), the Max Planck Institute for Polymer Research, Mainz, and the American National Institutes of Health (NIH) have now developed a new method to visualize cell structures of an eighth of a micrometer in size in living fish larvae. Read the Full Story
ScienceDaily (May 15, 2012) — Astrophysicists have just discovered a new heating source in cosmological structure formation. Until now, astrophysicists thought that super-massive black holes could only influence their immediate surroundings. A collaboration of scientists at the Heidelberg Institute for Theoretical Studies (HITS) and in Canada and the US have now discovered that diffuse gas in the universe can absorb luminous gamma-ray emission from black holes, heating it up strongly. This surprising result has important implications for the formation of structures in the universe. Read the Full Story
ScienceDaily (May 15, 2012) — Astrophysicists have just discovered a new heating source in cosmological structure formation. Until now, astrophysicists thought that super-massive black holes could only influence their immediate surroundings. A collaboration of scientists at the Heidelberg Institute for Theoretical Studies (HITS) and in Canada and the US have now discovered that diffuse gas in the universe can absorb luminous gamma-ray emission from black holes, heating it up strongly. This surprising result has important implications for the formation of structures in the universe. Read the Full Story
ScienceDaily (May 13, 2012) — Using tiny solar-panel-like cells surgically placed underneath the retina, scientists at the Stanford University School of Medicine have devised a system that may someday restore sight to people who have lost vision because of certain types of degenerative eye diseases. Read the Full Story
ScienceDaily (May 10, 2012) — A new study published in Science May 11 is shedding light on the molecular details of PARP-1, a DNA damage-detecting enzyme that when inhibited has been shown to be effective in fighting cancer and other diseases. Read the Full Story
ScienceDaily (May 14, 2012) — Prickly pufferfish could hold the key to why humans do not continually replace their teeth and may lead to advances in dental therapies. Read the Full Story
image Microscope Looks Into Cells of Living Fish
image Sulfur Finding May Hold Key to Gaia Theory of Earth as Living Organism
image Black Holes Turn Up the Heat for the Universe
image Tiny Solar-Panel-Like Cells Help Restore Sight to the Blind
image Why Inhibiting DNA Damage-Detecting Enzyme Is Effective in Fighting Cancer and Other Diseases
image Pufferfish at the 'Beak' of Evolution: Why Humans Don't Continuously Replace Their Teeth

BioScreening News

  • Evotec Becomes First European CRO to Offer Agilent’s RapidFire Screening Tool
    Evotec is adding Agilent Technologies’ RapidFire mass spectrometry analysis capabilities to its high-throughput screening facilities in Hamburg. RapidFire is an in-line solid-phase extraction technology. It enables ultrafast, direct analysis of native compounds for a variety of biochemical assays including routine ADME and lead discovery applications across a range of therapeutic...
  • Pfizer’s Torisel Misses Endpoints in Renal Cell Carcinoma Trial Testing Second-Line Setting
    Pfizer’s drug candidate for advanced renal cell carcinoma (RCC), Torisel, failed to meet the primary endpoint of progression-free survival in the Phase III Intorsect study. The trial compared Torisel and Nexavar in patients whose disease had progressed on or after treatment with the company’s approved drug Sutent. Although PFS was...
  • Lonza, Avalanche Partner on Baculovirus-Based AAV Manufacturing Platform
    Biologics manufacturer Lonza and ocular gene therapy specialist Avalanche Biotechnologies established a global manufacturing collaboration to aid in the latter’s gene therapy programs. Avalanche’s lead wet age-related macular degeneration (wet-AMD) gene therapy candidate AVA-101 started in early clinical trials at the end of 2011. The partnership will focus on the...
  • IntelligentMDx Wins CE Mark for Group B Strep Assay on Abbott m2000 Instrument
    IntelligentMDx received a CE Mark for its qualitative Group B Streptococcus (GBS) in vitro diagnostic, IMDx GBS, for use on the Abbott m2000™ system. The assay is used to screen for Group B Streptococcus infection in at-risk pregnant women and women in labor. The real-time PCR test can be carried...
  • Admescope to Provide PlexPress Multiplex CYP Gene Expression Analysis Technology
    CRO Admescope will offer PlexPress’ TRAC (transcript analysis with the aid of affinity capture) platform for high-throughput gene expression analysis as part of its in vitro drug interaction and preclinical ADME-Tox services. Finland-based Admescope will initially offer Plexpress’ multiplex cytochrome P450 (CYP) assays. The firm says the service will meet...
  • Six Suitors Join Bristol-Myers in Considering a Bid for Amylin
    After turning down an unsolicited bid from Bristol-Myers Squibb (BMS) in February, Amylin Pharmaceuticals is preparing to weigh offers from BMS and up to six other potential suitors. Citing unnamed “people familiar with the matter,” Bloomberg News reported that BMS has joined AstraZeneca, Merck & Co., Pfizer, Roche, Sanofi, and...
  • Accelr8, Denver Health Win $2M to Develop Battlefield Infections Diagnostic
    Accelr8 and Denver Health received notification that the Defence Medical Research and Development Program (DMRPD) has recommended a $2 million award to support a three-year project focused on developing a rapid diagnostic system for wound infections and serious infections secondary to trauma. The project was the sole recipient of funds...
  • Gamida Cell Raises $10M to Progress Phase III-Stage Hematologic Cancer Cell Therapy
    Gamida Cell raised $10 million through an internal Series E financing round with all its existing major shareholders. The proceeds will be used to support global commercialization of the firm’s Phase III-stage StemEx cord blood stem cell therapy for blood cancers, and continue development of additional pipeline candidates, including clinical...
  • ALS Institute, Neurotune to Evaluate Amyotrophic Lateral Sclerosis Therapeutic Candidate
    The ALS Therapeutic Institute and Neurotune established a collaboration to evaluate one of the latter’s neuromuscular diseases candidates in an ALS disease model. ALS is associated with motor neurons and their axons becoming disconnected from muscle, and Neurotune has identified a class of compounds designed to maintain neuromuscular junction strength...
  • KineMed, CHDI Ally on Biomarkers of Huntington Disease Progression, Drug Efficacy
    CHDI Foundation and KineMed established a collaboration to exploit the latter’s tandem mass spectrometry-based proteomics platform to analyze the in vivo dynamics of mutant huntingtin protein as a means of assessing Huntington disease progression and measuring the efficacy of therapeutic candidates. The aim is to generate data that will both...

Life Science Events

April 2012 May 2012 June 2012
Su Mo Tu We Th Fr Sa
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31
Recent events
View full calendar
1 DOW 12,558.25
-40.30 (-0.32%)    
2 S&P 1,320.89
-3.91 (-0.30%)    
3 NASDAQ 2,860.75
-13.29 (-0.46%)